Comerica Bank’s Viking Therapeutics VKTX Stock Holding History

Comerica Bank’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$122K	Sell	3,460 -627	-15%	-$22.2K	﹤0.01%	2548
2025 Q3	$107K	Sell	4,087 -43,716	-91%	-$1.3M	﹤0.01%	2584
2025 Q2	$1.27M	Buy	47,803 +8,509	+22%	+$224K	﹤0.01%	1386
2025 Q1	$949K	Sell	39,294 -20,767	-35%	-$656K	﹤0.01%	1536
2024 Q4	$2.42M	Sell	60,061 -137,322	-70%	-$7.83M	0.01%	1048
2024 Q3	$12.5M	Buy	197,383 +55,145	+39%	+$3.24M	0.05%	359
2024 Q2	$7.54M	Buy	142,238 +50,695	+55%	+$3.32M	0.03%	492
2024 Q1	$7.51M	Buy	91,543 +91,219	+28,154%	+$4.06M	0.03%	518
2023 Q4	$6.03K	Buy	324 +33	+11%	+$432	﹤0.01%	3273
2023 Q3	$3.22K	Buy	+291	New	+$4.16K	﹤0.01%	3477

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Comerica Bank's VKTX Position: Q4 2025 in Review

Comerica Bank reduced its Viking Therapeutics (VKTX) stake by 15% in Q4 2025, selling an estimated $22.2K and leaving 3,460 shares worth $122K. The position accounts for ﹤0.01% of the portfolio, ranked #2548.

Comerica Bank first reported a position in VKTX in Q3 2023 and has held it in 10 quarters since. The position peaked at $12.5M in Q3 2024. 426 funds tracked by Wall St. Rank hold VKTX as of Q4 2025.

Comerica Bank held 3,460 shares of Viking Therapeutics worth $122K as of Q4 2025.
Comerica Bank sold 627 Viking Therapeutics shares in Q4 2025, an estimated $22.2K.
Viking Therapeutics made up ﹤0.01% of Comerica Bank's portfolio in Q4 2025, its #2548 holding.
Comerica Bank first reported a position in Viking Therapeutics in Q3 2023 and has held it in 10 quarters since.
Comerica Bank's Viking Therapeutics position peaked at $12.5M in Q3 2024.
426 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2025.

Based on Comerica Bank's 13F filing for Q4 2025, filed 29 Jan 2026.